Novartis gains FDA approval for Afinitor® as first new treatment in nearly three decades for patients with advanced pancreatic NET
Posted on May 07, 2011 at 04:44 AM EDT
Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease[4]. This marks the first approval of a treatment for this patient population in the US in nearly 30 years[5].